Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity

Feasibility of a Microarray-Based Point-of-Care CYP2C19 Genotyping Test for Predicting Clopidogrel On-Treatment Platelet Reactivity

Clopidogrel is a prodrug which is converted into active metabolite by cytochrome P450 isoenzyme, CYP2C19. Numerous polymorphisms of CYP2C19 are reported, and a strong link exists between loss-of-function (LOF) or gain-of-function polymorphisms, clopidogrel metabolism, and clinical outcome. Hence, a...

Full description

Bibliographic Details
Main Authors: Chae, Hyojin, Kim, Myungshin, Koh, Yoon-Seok, Hwang, Byung-Hee, Kang, Min-Kyu, Kim, Yonggoo, Park, Hae-il, Chang, Kiyuk
Format: Online
Language:English
Published: Hindawi Publishing Corporation 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625605/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625605/

Similar Items